Bio-Rad Laboratories Class A
BIO
328 hedge funds and large institutions have $4.43B invested in Bio-Rad Laboratories Class A in 2018 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 116 increasing their positions, 118 reducing their positions, and 62 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
0.02% more ownership
Funds ownership: 76.93% → 76.95% (+0.02%)
2% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 118
4% less funds holding
Funds holding: 343 → 328 (-15)
24% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 62
25% less capital invested
Capital invested by funds: $5.95B → $4.43B (-$1.51B)
32% less call options, than puts
Call options by funds: $5.47M | Put options by funds: $8.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$151M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$52.4M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$42.9M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$24M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$22.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$153M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$34.6M |
| 3 |
Select Equity Group
New York
|
-$34.2M |
| 4 |
BC
Bodenholm Capital
Stockholm,
Sweden
|
-$32.5M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$32.1M |
BIO Hedge Fund Activity: Q4 2018 in Review
328 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2018, worth a combined $4.43B — down 25% from $5.95B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of BIO and 47 opened new positions — a net loss of 15 holders — while 118 trimmed existing stakes and 116 added.
The largest buyer was Levin Capital Strategies, adding an estimated $151M. The largest seller was Atlanta Capital Management, cutting an estimated $153M.
- 328 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2018, down from 343 in Q3 2018.
- Funds reported $4.43B of Bio-Rad Laboratories Class A stock for Q4 2018, down 25% quarter-over-quarter.
- 47 funds opened new Bio-Rad Laboratories Class A positions in Q4 2018 and 62 closed out, a net change of -15 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q4 2018 was Levin Capital Strategies, an estimated $151M added.
- The largest Bio-Rad Laboratories Class A seller in Q4 2018 was Atlanta Capital Management, an estimated $153M sold.
Based on aggregated 13F filings for Q4 2018.